

Amgen Inc. IMDELLTRA® (tarlatamab-dlle) Background References

[Siegel RL, et al.](#) Cancer statistics, 2022. *CA Cancer J Clin.* 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12

[Sabari JK, et al.](#) Unravelling the biology of SCLC: implications for therapy. *Nat Rev Clin Oncol.* 2017;14:549-56.

[SEER*Explorer: An interactive website for SEER cancer statistics.](#) Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [updated: 2024 Nov 5; cited 2025 Apr 14].

[Slotman B, et al.](#) Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med.* 2007;357:664-672.

[Takahashi T, et al.](#) Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2017;18(5):663-671.

[Paz-Ares L, et al.](#) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet.* 2019;394:1929-1939.

[Horn L, et al.](#) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med.* 2018;379:2220-2229.

[von Pawel J, et al.](#) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol.* 1999;17:658-667.

[von Pawel J, et al.](#) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. *J Clin Oncol.* 2014;32:4012-4019.

[Farago AF, et al.](#) ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. *Future Oncol.* 2019;15:231-239.

[Trigo J, et al.](#) Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. *Lancet Oncol.* 2020;21:645-654.

[Onoda S, et al.](#) Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. *J Clin Oncol.* 2006;24:5448-5453.

[Horita N, et al.](#) Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients. *Sci Rep.* 2015;5:15437.

[Owen DH, et al.](#) DLL3: an emerging target in small cell lung cancer. *J Hematol Oncol.* 2019;12(1):61.

[Paz-Ares L, et al.](#) Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. *J Clin Oncol.* 2023;41(16):2893-2903.